Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women

References

• Moore RA.Livial – a review of clinical studies. Br J Obstet Gynaecol 1999;19:1–21.
   Google Scholar
• Lloyd GW, Patel NR, McGing EA, Cooper AF, Kamalvand K, Jackson G.Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. Int J Clin Pract 1998;52:155–157.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H.Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecol Endocrinol 2006;22:163–173.
   PubMed Web of Science ®Google Scholar
• Koh KK, Yoon BK.Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22–30.
   PubMed Web of Science ®Google Scholar
• Vassalle C, Boni C, Di Cecco P, Ndreu R, Zucchelli GC.Automation and validation of a fast method for the assessment of in vivo oxidative stress levels. Clin Chem Lab Med 2006;44:1372–1375.
   PubMed Web of Science ®Google Scholar
• Vassalle C, Masini S, Carpeggiani C, L'Abbate A, Boni C, Zucchelli GC.In vivo total antioxidant capacity: comparison of two different analytical methods. Clin Chem Lab Med 2004;42:84–89.
   PubMed Web of Science ®Google Scholar
• Vassalle C.An easy and reliable automated method to estimate oxidative stress in the clinical setting. Methods Mol Biol 2008;477:31–39.
   PubMedGoogle Scholar
• Rosano GM, Vitale C, Marazzi G, Volterrani M.Menopause and cardiovascular disease: the evidence. Climacteric 2007;10:19–24.
   PubMed Web of Science ®Google Scholar
• Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP.A cross-sectional study on the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy post-menopausal women. Fertil Steril 2002;77:945–951.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Ranieri G, Maffei S, Colafiglio G, Ria R, Bellavia M, Schonauer MM.Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women. Fertil Steril 2006;86:899–904.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A.Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas 2004;48:155–160.
   PubMed Web of Science ®Google Scholar
• Lloyd G, McGing E, Cooper A, Patel N, Lumb PJ, Wierzbicki AS, et al A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99–104.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Stramba-Badiale M, Mercuro G.Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown). 2009;10:85–92.
   PubMed Web of Science ®Google Scholar
• Hardiman P, Nihoyannopoulos P, Kicovic P, Ginsburg J.Cardiovascular effects of ORG OD 14 – a new steroid therapy for climacteric symptoms. Maturitas 1991;13:235–242.
   PubMed Web of Science ®Google Scholar
• Korstjens IJ, Smolders RG, van der Mooren MJ, Kloosterboer HJ, Kenemans P, Sipkema P.Endothelium-dependent dilatory effects of 3alpha-OH-tibolone in gracilis muscle arterioles of the female Wistar rat. Menopause 2005;12:340–347.
   PubMed Web of Science ®Google Scholar
• Schenck-Gustafsson K.Risk factors for cardiovascular disease in women. Maturitas 2009;63:186–190.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB.Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997;82:251–253.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Starflinger F, Tetzloff W, Leifels-Fischer B, Helmond FA, Dericks-Tan JS, et al Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas 2002;41:133–141.
   PubMed Web of Science ®Google Scholar
• Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H.Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005;84:384–393.
   PubMed Web of Science ®Google Scholar
• Saucedo RP, Basurto L, Fonseca E, Zarate A.Effect of hormone replacement with tibolone on plasma insulin and blood glucose in postmenopause. Ginecol Obstet Mex 2001;69:301–303.
   PubMedGoogle Scholar
• Prelevic GM, Beljic T, Balint-Peric L, Ginsburg J.Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas 1998;28:271–276.
   PubMed Web of Science ®Google Scholar
• Odmark IS, Carlstrom K, Jonsson B, Jonasson AF.Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin. Maturitas 2006;53:89–96.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Herrington DM.Effects of oestrogen receptor-active compounds on lipid metabolism. Diabetes Obes Metab 2005;7:471–477.
   PubMed Web of Science ®Google Scholar
• Campisi R, Marengo FD.Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. Cardiovasc Drug Rev 2007;25:132–145.
   PubMed Web of Science ®Google Scholar
• Skouby SO, Sidelmann JJ, Nilas L, Gram J, Jespersen J.The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. Climacteric 2008;11:489–497.
   PubMed Web of Science ®Google Scholar
• Daher R, Al-Amin H, Beaini M, Usta I.Effect of tibolone therapy on lipids and coagulation indices. Clin Chem Lab Med 2006;44:1498–1499.
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C.Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752–1756.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A, Anderson P, Cox P, Hoszowski K, et al the MORE (Multiple Outcomes of Raloxifene Evaluation) Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847–857.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Anthony MS, Mikkola TS, St Clair RW.Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke 2002;33:2700–2703.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Nofer JR, Assmann G.High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13–27.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Anthony MS, Clarkson TB, St. Clair RW.Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugate estrogens. Metabolism 2002;51:523–530.
   PubMed Web of Science ®Google Scholar
• Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, et al Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 2005;12:552–558.
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK.Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005 ;26:1362–1368.
   PubMed Web of Science ®Google Scholar
• Ostberg JE, Damjanovic T, Dimkovic N, Byrne D, Mikhailidis DP, Prelevic GM.Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil Steril 2004;81:1624–1631.
   PubMed Web of Science ®Google Scholar
• Koh KK, Ahn JY, Jin DK, Yoon BK, Kim HS, Kim DS, et al Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889–1894.
   PubMed Web of Science ®Google Scholar
• Barnes JF, Farish E, Rankin M, Hart DM.Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 2005;12:92–98.
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM.Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Homeos 2008;6:928–934.
   PubMed Web of Science ®Google Scholar
• Vural P, Canbaz M, Akgul C.Effects of menopause and postmenopausal tibolone treatment on plasma TNFalpha, IL-4, IL-10, IL-12 cytokine pattern and some bone turnover markers. Pharmacol Res 2006;53:367–371.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–529.
   PubMed Web of Science ®Google Scholar
• Vural P, Akgül C, Canbaz M.Effects of menopause and tibolone on antioxidants in postmenopausal women. Ann Clin Biochem 2005;42:220–223.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
   PubMed Web of Science ®Google Scholar
• Cook NR, Buring JE, Ridker PM.The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21–29.
   PubMed Web of Science ®Google Scholar
• Vassalle C, Maffei S, Boni C, Zucchelli GC.Gender-related differences in oxidative stress levels among elderly patients with coronary artery disease. Fertil Steril 2008;89:608–613.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, et al, for the LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708.
   PubMed Web of Science ®Google Scholar
• Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den Hollander W, Stathopoulos V, Helmond F.Endometrial effects of tibolone for the tibolone histology of the endometrium and breast endpoints (THEBES) study group. JCEM 2007;92:911–918.
   PubMed Web of Science ®Google Scholar
• Roussow JE, Prentice RL, Manson JE, Wu LLW, Barad D, Barnabei VM, Ko M, Lacroix AZ, Margolis KL, Stefanick ML.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477.
   PubMed Web of Science ®Google Scholar
• Good AE.Hormone therapy in menopause: the plot thickens. Minn Med 2003;86:32–35.
   PubMedGoogle Scholar